State Of Washington, V. Amber Lynn Fitzgerald
Opinion
Filed
Washington State
Court of Appeals
Division Two
January 24, 2023
IN THE COURT OF APPEALS OF THE STATE OF WASHINGTON
DIVISION II
STATE OF WASHINGTON, No. 56225-1-II (consolidated with No. 56231-6-II)
Respondent,
v.
AMBER LYNN FITZGERALD, UNPUBLISHED OPINION Appellant.
GLASGOW, C.J.—In two separate incidents, Amber Lynn Fitzgerald assaulted three nurses and a hospital security guard. Under two separate cause numbers, the State charged her with three counts of third degree assault and one count of fourth degree assault.
At Fitzgerald’s request, the trial court transferred her cases to drug court. As a condition of participating in drug court, Fitzgerald agreed to pay costs associated with the program and acknowledged that she would still owe those costs if she were terminated from drug court. The court entered two judgments imposing drug court costs as she entered the program.
After about a year and a half, Fitzgerald was terminated from drug court due to noncompliance. At the stipulated bench trial that followed, the trial court found her guilty of all four counts. At sentencing, the trial court entered two judgment and sentences, imposing two mandatory $500 crime victim penalty assessments and the $100 DNA collection fee. But the trial court did not revisit the drug court costs. After the sentencing, the trial court entered an order striking the $100 DNA collection fee because the parties and the court agreed that Fitzgerald
qualified for waiver under former RCW 9.94A.777 (2010) of nonmandatory, nonrestitution legal financial obligations based on a mental health diagnosis.
Fitzgerald appeals, arguing that the trial court should have revisited the drug court costs at sentencing and was required to conduct an individualized inquiry into her ability to pay them at that time. She also contends the trial court should have included in her judgment and sentence language preventing collection of legal financial obligations from Social Security income.
We conclude that Fitzgerald failed to appeal the judgments imposing the drug court costs, and she fails to establish that the trial court had an obligation to revisit previously imposed drug court costs during sentencing. However, when the trial court revisited Fitzgerald’s legal financial obligations under former RCW 9.94A.777(1) postsentencing, it should have also reconsidered her drug court fee obligations at that time.
We remand for the trial court to revisit Fitzgerald’s drug court fees in light of the parties’
agreement under former RCW 9.94A.777. We reject Fitzgerald’s contention that the judgment and sentences should be amended to add provisions about Social Security income.
FACTS
In July 2019, Fitzgerald was at a hospital when she punched one nurse and bit and spat on another. In August 2019, she spat on a third nurse and bit a security guard at the same hospital. The State charged her with two counts of third degree assault for the first incident and one count each of third and fourth degree assault for the second incident.
In February 2020, Fitzgerald petitioned to enter drug court for both cases. Fitzgerald filed two substantially identical agreements for entry into the drug court program, one for each cause number. The agreements stated that if Fitzgerald’s treatment program was terminated, her cases
would “proceed directly to a bench trial.” Clerk’s Papers (CP) at 10, 191. The agreements also had a financial component: “Petitioner will pay all fees determined to be within [her] ability to pay. If [she] is removed from the program, all those fees are still due and owing.” CP at 11, 192. Additionally, Fitzgerald filed two confession and stipulations for entry into the drug court program. In the first confession and stipulation, Fitzgerald admitted that in July 2019, she assaulted two nurses. In the second, Fitzgerald admitted that in August 2019, she assaulted a nurse and a security guard.
The same day, the trial court accepted Fitzgerald’s petitions and transferred her cases to drug court. The trial court also entered two separate judgments against Fitzgerald for the costs of drug court participation. For the July 2019 assaults, the trial court imposed a $200 filing fee, a $100 “[c]ollector [f]ee,” and a $775 drug court fee, totaling $1,075 in fees. CP at 19. For the August 2019 assaults, the trial court imposed a $200 filing fee and a $100 “[c]ollector [f]ee.” CP at 200. However, it waived the $775 drug court fee. The total costs imposed in these two judgments amounted to $1,375. Neither party designated for our record any 2020 hearings regarding Fitzgerald’s entry into drug court, so we do not know whether the trial court addressed her ability to pay at that time.
Fitzgerald was terminated from drug court due to noncompliance in September 2021. A stipulated bench trial followed. The trial court found Fitzgerald guilty of all charges. During sentencing, Fitzgerald’s counsel stated, “I am going to assist Ms. Fitzgerald with following up with Social Security Disability, so we can hopefully assist her with that.” Verbatim Rep. of Proc. (VRP) (Sept. 7, 2021) at 205. The trial court imposed two mandatory $500 crime victim penalty assessments on Fitzgerald and assessed a $100 DNA collection fee to one of the cases, stating that
it would “make no other imposition” of legal financial obligations. Id. at 207. Neither the parties nor the trial court mentioned drug court costs at sentencing or in the judgment and sentences.
Several weeks later, Fitzgerald’s counsel explained that she and the prosecuting attorney agreed that “the DNA fee can be waived” under former RCW 9.94A.777 because Fitzgerald had mental health issues that prevented her from obtaining full employment. VRP (Oct. 15, 2021) at 212. The trial court agreed to waive the DNA collection fee. The trial court entered an order amending the judgment and sentence that contained the $100 DNA collection fee, removing the assessment of that fee. Thus, the judgment and sentences imposed only the mandatory $500 crime victim assessments, which at the time could not be waived under former RCW 9.94A.777.1 Fitzgerald appealed only the 2021 judgment and sentences. She did not appeal the 2020 judgments imposing drug court costs.
ANALYSIS
I. FAILURE TO REVISIT DRUG COURT COSTS AT SENTENCING Fitzgerald argues that the trial court abused its discretion by failing “to conduct an individualized financial inquiry into” Fitzgerald’s “current and future ability to pay” $1,375 in drug court costs. Appellant’s Opening Br. at 6. Instead of challenging the judgments imposing drug court fees directly, Fitzgerald contends that the trial court should have revisited the drug court
1 RCW 9.94A.777 was amended effective January 1, 2023. It now permits a court to waive the victim penalty assessment as well if the defendant satisfies the requirements set forth in that section. Id.
fees at sentencing or afterward when the trial court determined that the DNA collection fee could be waived under former RCW 9.94A.777 based on Fitzgerald’s mental health issues.2 The State points out that Fitzgerald did not raise drug court costs during sentencing below or otherwise challenge them. The State also relies on Fitzgerald’s agreement to pay drug court fees. A. RAP 2.5(a) Discretion RAP 2.5(a) grants appellate courts discretion to review issues raised for the first time on appeal. State v. Blazina, 182 Wn.2d 827, 834-35, 344 P.3d 680 (2015). As the Washington Supreme Court has explained, legal financial obligations carry problematic consequences. Id. at 836-37. Here, we exercise our discretion under RAP 2.5(a) to address whether the trial court should have revisited drug court costs at sentencing or after sentencing when the trial court waived the $100 DNA collection fee under former RCW 9.94A.777.
Free access — add to your briefcase to read the full text and ask questions with AI
State Of Washington, V. Amber Lynn Fitzgerald (State Of Washington, V. Amber Lynn Fitzgerald) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.